

**Meeting Minutes  
Vaccine Committee Meeting  
November 7, 2024; 11:30 a.m. – 12:30 p.m. PT**

**I. Attendance.** This meeting was conducted in-person and virtually. Participating in all or part of the meeting were the following individuals:

<p>8 <u>Members</u></p> <p>9 Ed Marcuse, MD, Emeritus Professor of</p> <p>10 Pediatrics, University of Washington, <i>Chair</i></p> <p>11 Amy Carter, MD, Allegro Pediatrics (virtual)</p> <p>12 John Dunn, MD, MPH, Kaiser</p> <p>13 Libby Page, MPH, King County Public Health</p> <p>14 (virtual)</p> <p>15 Jeff Gombosky, Pharmaceutical Research and</p> <p>16 Manufacturers of America (virtual)</p> <p>17 Carrie Jenner, MD, Pierce County Immunization</p> <p>18 Coalition (PCIC) (virtual)</p> <p>19 Jamilia Sherls-Jones, DNP, MPH, Washington</p> <p>20 Department of Health</p> <p>21 Amy Person, MD, Benton-Franklin Health District</p> <p>22 (virtual)</p> <p>23 Kristi A. Rice, MD, Providence (virtual)</p> <p>24 Sherri Zorn, MD, DOH &amp; WVA Consultant</p>	<p>26 <u>WVA</u></p> <p>27 Julia G. Zell, MA, Esq., Executive Director</p> <p>28 Cheri Cagle, Stakeholder Liaison</p> <p>29</p> <p>30 <u>Helms &amp; Company, Inc.</u></p> <p>31 Patrick Miller, MPH, WVA, Administrative</p> <p>32 Director</p> <p>33 Ashley Ithal, MPH, Project Support Leader (virtual)</p> <p>34</p> <p>35 <u>Other</u></p> <p>36 Breelyn Young, GSK</p> <p>37 Eric Jacobsen, GSK (virtual)</p> <p>38 Lisa Templeton, Informed Choice WA (virtual)</p> <p>39</p> <p>40</p> <p>41</p> <p>42</p>
--	--

**II. Summary of Actions Taken and/or Recommended**

Actions Taken (votes adopted)

- i. To approve Vaccine Committee meeting minutes March 7, 2024.

**III. Minutes**

Welcome and Introductions

At 11:39 a.m. Dr. Marcuse called the meeting to order and announced that the meeting would be recorded for the benefit of the minute taker, to be deleted once the minutes are approved.

Calendar Consent Items

Dr. Marcuse asked for a motion to approve the minutes. Upon motion duly made and seconded, it was unanimously

- i. VOTED: To approve Vaccine Committee meeting minutes March 7, 2024.**

Review of Prior Year Milestones

Ms. Zell reported on the year-long effort to finance pediatric RSV vaccines and bring over 34 birthing hospitals into compliance with WVA assessment requirements. She explained that while working with hospitals to create a dosage-based assessment (DBA) mechanism for in-hospital patients receiving state-supplied vaccines, the WVA Board also identified other provider types that have not been creating assessments, but are enrolled in the Washington State Childhood Vaccination Program (CVP). Provider onboarding efforts are ongoing and policy decisions about non-compliant providers will be discussed by the Board

HCA/WVA Billing Guidance

Ms. Zell noted that the Washington State Health Care Authority (HCA) updated their billing guidance this year, which has caused some confusion amongst providers in relation to WVA's DBA submission guidance. Ms. Cagle wrote a synopsis of these changes that was previously distributed to the Committee and sent to providers requesting additional aid

Office Experiences & Challenges

73 Dr. Carter commended the Washington Department of Health (DOH) for improvements in the CVP process;  
74 however, she noted that vaccine supply timeliness remains an issue. She explained her practice’s challenges and  
75 made suggestions for improvement. Dr. Rice stated there were oversupply issues in previous years, and constraints  
76 this year. Dr. Jenner reported concerns with being unable to order entire vaccine supply at one time and that  
77 staggered delivery was challenging for her Vaccine Coordinator. Discussion ensued.  
78

79 The issue of recent shipment issues related to McKesson’s depot was raised. Ms. Sherls reported that the DOH is  
80 working with their Centers for Disease Control and Prevention (CDC) Project Officer to attempt to prevent future  
81 issues. Ms. Sherls gave an update on the DOH vaccine allocation process and status by vaccine type. She concluded  
82 with an update on RSV vaccine administration numbers from the DOH immunization dashboard.  
83

84 WVA Update on Immediate Challenges

85  
86 *Rebuilding Cash Reserves*

87 Ms. Zell reviewed the CY2023 and CY2024 cumulative impacts on cash reserves including pre-funding 2023 RSV  
88 vaccines, pre-funding Fall 2024 influenza, COVID, and RSV vaccines, and the amount recouped. Ms. Zell and Mr.  
89 Miller highlighted WVA’s plans to rebuild reserves in the next few years.  
90

91 *Renewing DOH WVA MOU*

92 Dr. Marcuse reported that the WVA is working with the DOH on renewing the DOH-WVA Memorandum of  
93 Understanding around certain fees paid to support vaccine distribution costs that is set to expire at the end of 2024.  
94

95 *Addressing Cybersecurity*

96 Ms. Zell reported that the WVA recently conducted a security risk assessment (SRA) with Stoel Rives LLP. There  
97 were some findings that the WVA addressed immediately, and others that will take more time to mitigate and are less  
98 time sensitive. The WVA will conduct future SRAs annually.  
99

100 WVA Vaccine Committee Charter Discussion

101 Dr. Marcuse reviewed the current version of the WVA Vaccine Committee Charter while providing the history behind  
102 why the original charter was created. He requested feedback on potential changes and activities the Committee could  
103 undertake.  
104

105 **IV. Public Comments – none.**

106  
107 **V. Closing**

108  
109 The meeting adjourned at 12:28 p.m. PT.